Helicobacter pylori seropositivity and risk of lung cancer

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Koshiol, Jill ^a   Flores, Roberto ^a   Lam, Tram K ^a   Taylor, Philip R ^a   Weinstein, Stephanie J ^a   Virtamo, Jarmo ^b   Albanes, Demetrius ^a   Perez Perez, Guillermo ^c   Caporaso, Neil E ^a   Blaser, Martin J ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; BETA CAROTENE; CAGA PROTEIN; IMMUNOGLOBULIN G; RETINOL; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; CAGA PROTEIN, HELICOBACTER PYLORI; PLACEBO;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CIGARETTE SMOKING; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; ETHNIC GROUP; FEMALE; FINNISH; HELICOBACTER PYLORI; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG CARCINOGENESIS; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; ADENOCARCINOMA; BLOOD; CASE CONTROL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HELICOBACTER INFECTION; LUNG TUMOR; METABOLISM; MICROBIOLOGY; MIDDLE AGED; QUESTIONNAIRE; REGRESSION ANALYSIS; RISK; SMOKING; SQUAMOUS CELL CARCINOMA;

HELICOBACTER PYLORI;

ADENOCARCINOMA; AGED; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; COHORT STUDIES; DOUBLE-BLIND METHOD; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ODDS RATIO; PLACEBOS; QUESTIONNAIRES; REGRESSION ANALYSIS; RISK; SMOKING;

EID: 84857612146     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032106     Document Type: Article

References (46)

1. Parkin DM, Bray F, Ferlay J, Pisani P, (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108.
2. Thun MJ, Henley SJ, Calle EE, (2002) Tobacco use and cancer: an epidemiologic perspective for geneticists. Oncogene 21: 7307-7325.
3. Engels EA, (2008) Inflammation in the development of lung cancer: epidemiological evidence. Expert Rev Anticancer Ther 8: 605-615.
4. Sun S, Schiller JH, Gazdar AF, (2007) Lung cancer in never smokers-a different disease. Nat Rev Cancer 7: 778-790.
5. Chaturvedi AK, Caporaso NE, Katki HA, Wong HL, Chatterjee N, et al. (2010) C-reactive protein and risk of lung cancer. J Clin Oncol 28: 2719-2726.
6. Pine SR, Mechanic LE, Enewold L, Chaturvedi AK, Katki HA, et al. (2011) Increased Levels of Circulating Interleukin 6, Interleukin 8, C-Reactive Protein, and Risk of Lung Cancer. J Natl Cancer Inst 103: 1112-1122.
7. Brenner DR, McLaughlin JR, Hung RJ, (2011) Previous lung diseases and lung cancer risk: a systematic review and meta-analysis. PLoS ONE 6: e17479.
8. Koshiol J, Rotunno M, Consonni D, Cecilia Pesatori AC, De Matteis S, et al. (2009) Chronic obstructive pulmonary disease and altered risk of lung cancer in a population-based case-control study. PLoS ONE 4: e7380.
9. Kohno T, Kunitoh H, Mimaki S, Shiraishi K, Kuchiba A, et al. (2011) Contribution of the TP53, OGG1, CHRNA3, and HLA-DQA1 Genes to the Risk for Lung Squamous Cell Carcinoma. J Thorac Oncol 6: 813-817.
10. Kohno T, Kunitoh H, Shimada Y, Shiraishi K, Ishii Y, et al. (2010) Individuals susceptible to lung adenocarcinoma defined by combined HLA-DQA1 and TERT genotypes. Carcinogenesis 31: 834-841.
11. Gillison ML, Chaturvedi AK, Lowy DR, (2008) HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer 113: 3036-3046.
12. Parkin DM, (2006) The global health burden of infection-associated cancers in the year 2002. Int J Cancer 118: 3030-3044.
13. Ece F, F Hatabay N, Erdal N, Gedik C, Guney C, et al. (2005) Does Helicobacter pylori infection play a role in lung cancer? Respir Med 99: 1258-1262.
14. Gocyk W, Niklinski T, Olechnowicz H, Duda A, Bielanski W, et al. (2000) Helicobacter pylori, gastrin and cyclooxygenase-2 in lung cancer. Med Sci Monit 6: 1085-1092.
15. Brenner H, Rothenbacher D, Arndt V, (2009) Epidemiology of stomach cancer. Methods Mol Biol 472: 467-477.
16. Kanbay M, Kanbay A, Boyacioglu S, (2007) Helicobacter pylori infection as a possible risk factor for respiratory system disease: a review of the literature. Respir Med 101: 203-209.
17. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (1994) Schistosomes, liver flukes and Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum 61: 1-241.
18. Tegtmeyer N, Wessler S, Backert S, (2011) Role of the cag-pathogenicity island encoded type IV secretion system in Helicobacter pylori pathogenesis. FEBS J 278: 1190-1202.
19. Arnold IC, Dehzad N, Reuter S, Martin H, Becher B, et al. (2011) Helicobacter pylori infection prevents allergic asthma in mouse models through the induction of regulatory T cells. J Clin Invest 121: 3088-3093.
20. Chang YJ, Kim HY, Albacker LA, Lee HH, Baumgarth N, et al. (2011) Influenza infection in suckling mice expands an NKT cell subset that protects against airway hyperreactivity. J Clin Invest 121: 57-69.
21. Islami F, Kamangar F, (2008) Helicobacter pylori and esophageal cancer risk: a meta-analysis. Cancer Prev Res (Phila Pa) 1: 329-338.
22. Janssen-Heijnen ML, Coebergh JW, (2003) The changing epidemiology of lung cancer in Europe. Lung Cancer 41: 245-258.
23. Najafizadeh K, Falah Tafti S, Shiehmorteza M, Saloor M, Jamali M, (2007) H pylori seroprevalence in patients with lung cancer. World J Gastroenterol 13: 2349-2351.
24. Philippou N, Koursarakos P, Anastasakou E, Krietsepi V, Mavrea S, et al. (2004) Helicobacter pylori seroprevalence in patients with lung cancer. World J Gastroenterol 10: 3342-3344.
25. Behroozian R, Moradkhan E, (2010) The assessment of probable relationship between lung cancer and Helicobacter pylori infection. Trop Gastroenterol 31: 34-36.
26. Zhuo WL, Zhu B, Xiang ZL, Zhuo XL, Cai L, et al. (2009) Assessment of the relationship between Helicobacter pylori and lung cancer: a meta-analysis. Arch Med Res 40: 406-410.
27. Kamangar F, Dawsey SM, Blaser MJ, Perez-Perez GI, Pietinen P, et al. (2006) Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity. J Natl Cancer Inst 98: 1445-1452.
28. Stolzenberg-Solomon RZ, Blaser MJ, Limburg PJ, Perez-Perez G, Taylor PR, et al. (2001) Helicobacter pylori seropositivity as a risk factor for pancreatic cancer. J Natl Cancer Inst 93: 937-941.
29. Cook MB, Dawsey SM, Diaw L, Blaser MJ, Perez-Perez GI, et al. (2010) Serum pepsinogens and Helicobacter pylori in relation to the risk of esophageal squamous cell carcinoma in the alpha-tocopherol, beta-carotene cancer prevention study. Cancer Epidemiol Biomarkers Prev 19: 1966-1975.
30. Murphy G, Kamangar F, Dawsey SM, Stanczyk FZ, Weinstein SJ, et al. (2011) The relationship between serum Ghrelin and the risk of gastric and esophagogastric junctional adenocarcinomas. J Natl Cancer Inst 103: 1123-1129.
31. The ATBC Cancer Prevention Study Group (1994) The alpha-tocopherol, beta-carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. Ann Epidemiol 4: 1-10.
32. World Health Organization (1978) International statistical classifi cation of diseases and related health problems Geneva (Switzerland) World Health Organization.
33. Korhonen P, Malila N, Pukkala E, Teppo L, Albanes D, et al. (2002) The Finnish Cancer Registry as follow-up source of a large trial cohort-accuracy and delay. Acta Oncol 41: 381-388.
34. Limburg P, Qiao Y, Mark S, Wang G, Perez-Perez G, et al. (2001) Helicobacter pylori seropositivity and subsite-specific gastric cancer risks in Linxian, China. J Natl Cancer Inst 93: 226-233.
35. Reibman J, Marmor M, Filner J, Fernandez-Beros ME, Rogers L, et al. (2008) Asthma is inversely associated with Helicobacter pylori status in an urban population. PLoS ONE 3: e4060.
36. Romero-Gallo J, Perez-Perez GI, Novick RP, Kamath P, Norbu T, et al. (2002) Responses of endoscopy patients in Ladakh, India, to Helicobacter pylori whole-cell and Cag A antigens. Clin Diagn Lab Immunol 9: 1313-1317.
37. Rothman K, Greenland S, (1998) Modern epidemiology Philadelphia Lippincott-Raven.
38. Lubin JH, Caporaso NE, (2006) Cigarette smoking and lung cancer: modeling total exposure and intensity. Cancer Epidemiol Biomarkers Prev 15: 517-523.
39. Lubin JH, Kogevinas M, Silverman D, Malats N, Garcia-Closas M, et al. (2007) Evidence for an intensity-dependent interaction of NAT2 acetylation genotype and cigarette smoking in the Spanish Bladder Cancer Study. Int J Epidemiol 36: 236-241.
40. Lubin JH, Virtamo J, Weinstein SJ, Albanes D, (2008) Cigarette smoking and cancer: intensity patterns in the alpha-tocopherol, beta-carotene cancer prevention study in Finnish men. Am J Epidemiol 167: 970-975.
41. Kosunen TU, Aromaa A, Knekt P, Salomaa A, Rautelin H, et al. (1997) Helicobacter antibodies in 1973 and 1994 in the adult population of Vammala, Finland. Epidemiol Infect 119: 29-34.
42. Greenland S, Rothman KJ, (1998) Approximate statistics: the likelihood-ratio method. In: Rothman KJ, Greenland S, editors. Modern Epidemiology Philadelphia Lippincott Williams & Wilkins pp. 218-220.
43. Albanes D, Heinonen OP, Taylor PR, Virtamo J, Edwards BK, et al. (1996) Alpha-Tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance. J Natl Cancer Inst 88: 1560-1570.
44. Albanes D, Heinonen OP, Huttunen JK, Taylor PR, Virtamo J, et al. (1995) Effects of alpha-tocopherol and beta-carotene supplements on cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study. Am J Clin Nutr 62: 1427S-1430S.
45. Egger M, Smith GD, Phillips AN, (1997) Meta-analysis: principles and procedures. BMJ 315: 1533-1537.
46. Sterne JA, Gavaghan D, Egger M, (2000) Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 53: 1119-1129.